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Abstract Piemonte and Valle d'Aosta Interregional Network for Rare Diseases (RD) is a model of 
''diffuse'' network; it involves all the health system specialists devoted to the diagnosis, the therapy 
and the follow-up of a RD. The Consortium is a multidisciplinary team operating throughout the 
Region composed of volunteer Physicians and Biologists that promotes periodical meetings to 
develop shared protocols. In 2008 the Specialist-Technical Committee for the Interregional RD 
Network approved the set up of the ''Chiari and Syringomyelia Consortium'' (CSC) with two 
specific objectives: to identify the shared diagnostic criteria and to develop the interdisciplinary 
diagnostic-therapeutic-assistance path (DTAP) to be used interregionally. Other objectives are: to 
define the prevalence of the pathologies (both symptomatic and asymptomatic, both in adults and 
children) and to improve collaboration between the patient Associations and the Physicians.  
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Introduction  
 
According to the European Union Actions Plans, the Rare Diseases (RD) are life-threatening, 
chronically disabling pathologies, with such a low prevalence requiring a spe- cialists joint 
collaboration to prevent a significant pre- mature mortality or morbidity, i.e. a relevant reduction in 
the quality of life or in the socio-economical potential of the affected persons [1]. In Europe the 
chosen threshold value was lower than one individual out of 2,000 to define a disease as Rare. With 
this criteria 5-8,000 different RD have been diagnosed out of 15 million of people in Europe alone. 
The diagnosis and care for RD has been indicated as priorities for Public Health by the Italian 
National Health Plan (1999); in 2001 a specific National Law (Ministerial Decree 279/2001) set up 
the Italian National Network for RD to deal with the prevention surveillance, the diagnosis and the 
treatment of the RD [2]. The same law activated the RD National Register located at the National 
Institute of Health (NIH), which is expected to receive epidemiological data from regional centres. 
The DM 279/2001 determines the RD that have right to ticket exemption, e.g. Arnold- Chiari 
Syndrome (code RN0010) for the symptomatic Chiari Malformation (CM).  
Whilst the prevalence of Syringomyelia is known to be 8.4:100,000 [3], there are no available 
prevalence data for CM in Italy, because the case collection has started recently. A Regional Decree 
(2-03-2004, n. 22-11870) stated the Regional Network for the prevention, screening, diagnosis and 
therapy of Rare Diseases. Moreover it obli- ges the Regional Hospital Units to register RD in the 
Regional Network and sets up the Regional Centre for the Coordination of Rare Diseases [4]. A 
second decree (Regional Decree, 12-04-2005, n. 38-15326) sets up a Specialistic-Technical 
Committee to work in cooperation with the Regional Centre for the Coordination of RD and confers 
the benefits of the Ministerial Decree 279/2001 to about fifty RD [5], including Syringomyelia-
Syringobulbia (exemption code RF0321). In fact, Syringomyelia is recognised as RD only in a few 
Italian regions, such as Piemonte, Valle d'Aosta, Toscana and Marche.  
The Piemonte model of ''diffuse'' network is unique in Italy: it involves all the regional Health 
System specialists in the diagnosis, therapy and, above all, in the follow up and treatment. A crucial 
point of this model is carried out by the Consortium Activities, multidisciplinary groups, operating 
throughout the Region, composed by volunteer Physicians, Biologists and health care workers; they 
form working groups to enhance the research and the develop- ment of shared protocols for a 
standardized regional diagnostic-therapeutic approach.  
In 2008, the Consortium Activities were approved with the aim of developing a dedicated, 
interdisciplinary and shared interregional diagnostic-therapeutic assistance path (DTAP); the next 
step will be to define the prevalence of Syringomyelia and Chiari in Piemonte and Valle d'Aosta, 
with special reference in the classification in symptomatic and asymptomatic classes, that may have 
a quite different outcome and consequent needs for heath-care.  
 
Materials and methods  
 
The Interregional Piemonte and Valle d'Aosta CSC was promoted in Torino by Multidisciplinary 
Group for Chiari and Syringomyelia at CTO Hospital: this specialist team involves many branches 
of medicine and care (neurolo- gists/neurophysiologists, neurosurgeons, neuroradiologists, 
physiatrists, spinal-surgeons, foniatrists, neuro-urologists, pain specialists, psychologists and social 
workers, dedi- cated nursing).  
Its activities include the confirmation of the diagnosis and the patients selection for surgery, the 
planning of periodical Multidisciplinary Group evaluations both the surgical and non-surgical cases, 
the pre-surgical setup and post-surgical follow up and the identification of diagnostic- therapeutic 
protocols DTAP.  
The DTAP begins with the neurologist in a dedicated neurological outpatients department and 
involves the other specialists in various extents, depending on the course of the disease. When a 
patient presents with suspected or defined Chiari Syndrome or Syringomyelia, then the diagnosis is 
confirmed by the neurological team that cer- tifies it with an exemption request for RD. Instead, in 
the case of a preliminary diagnosis, a temporary exemption is supplied, to perform free diagnostic 
examinations further needed; after that, if the diagnosis is confirmed by the multidisciplinary team, 
the permanent exemption is given for free care and therapy. Whilst, if the disease is not confirmed, 
then the temporary exemption is not renewed.  
The CSC organization has many further phases, which includes: preparing diagnostic-therapeutic 
criteria and dif- ferentiated protocols (symptomatic/asymptomatic; child- hood/adulthood) as well 
as developing an interregional, shared DTAP.  
 
Results  
In a time span of a year, 102 patients were visited at the dedicated neurological outpatients 
department Chiari- Syringomyelia: 81 females, 21 males; 68 patients with radiological diagnosis of 
Chiari Malformation (65 CM-1 type and 3 CM-2 type; 37 isolated forms); 65 with radio- logical 
diagnosis of Syringomyelia (57 primary and 8 sec- ondary forms; 26 isolated forms). Thirty-one 
patients were syringomyelia-Chiari I complex (30%). Forty-one patients (60%) with diagnosis of 
CM (Arnold-Chiari Syndrome, exemption code code RN0010) and 38 (58%) syringomyelic 
patients (syntomatic Syringomyelia, exemption code code RF0321) obtained the exemption, 
according to Ministerial Decree 279/2001 and Regional Decree, 12-04-2005. Meetings on 
Syringomyelia and Chiari were organized by CSC in Torino, Cuneo and Alessandria to share diag- 
nostic-therapeutic criteria, to develop interregional proto- cols, to promote group research, to 
improve collaboration between patient Associations and physicians, to improve the relationships 
with the Italian Societies for Neurology, Neurosurgery and Rehabilitation.  
 
 
Discussions and conclusion 
Since 2005 in Piemonte and Valle d'Aosta there is a code for the patients affected by isolated 
Syringomyelia that avoids them from any expense for care or medication; whilst, the Chiari 
Syndrome patients have the complete exemption for RD in all the nation since 2001.  
In Piemonte and Valle d'Aosta Interregional Network for Rare Diseases activated the CSC, ''Chiari 
and Syrin- gomyelia'' Consortium, with the objective to obtain homogeneous diagnostic criteria, to 
develop a dedicated, interdisciplinary team and to share the same diagnostic- therapeutic paths in 
the two regions. Next step will be to define the prevalence of Syringomyelia and Chiari 
Malformation in Piemonte and Valle d'Aosta, with special reference to their clinical correlates 
(symptomatic and asymptomatic forms); moreover, it will organize health operators training 
programs, so enhancing the cooperation between the patients and the researchers.  
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